Decoy Therapeutics Inc. DCOY 深滬

等待開盤 01-27 09:30:00 美东时间

+0.023

+2.95%

華盛通

個股概要

美股大行评级 | 英特尔绩后获多家大行上调目标价；理想汽车、Mobileye、Meta、微软、甲骨文等遭下调目标价

今日重点评级关注：RBC Capital：维持Compass Pathways"跑赢大市"评级，目标价从16美元升至21美元；RBC Capital：维持GH Research"跑赢大市"评级，目标价从33美元升至40美元

01-26 14:32
Ladenburg Thalmann Initiates Coverage On Decoy Therapeutics with Buy Rating, Announces Price Target of $2.5

Ladenburg Thalmann analyst Kevin DeGeeter initiates coverage on Decoy Therapeutics (NASDAQ:DCOY) with a Buy rating and announces Price Target of $2.5.

01-23 20:29
Decoy Therapeutics Announces Funded Development Of Global Manufacturing Platform For Peptide‑Conjugate Antivirals Under Gates Foundation Access Agreement

Decoy Therapeutics will use the platform, with funding support from the Gates Foundation, to provide widespread access to peptide-conjugate antivirals from Decoy's IMP3ACT™ platform for low- and middle-income

01-13 21:20

公司名稱	Salarius Pharmaceuticals, Inc.
行業分類	Biotechnology
業務描述	Decoy Therapeutics, Inc. is a preclinical-stage biotechnology company that is leveraging machine learning and AI tools alongside high-speed synthesis techniques to rapidly design, engineer and manufacture peptide conjugate drug candidates that target serious unmet medical needs. The company is headquartered in Houston, TX.

派息除權日	每股總股息	派息日期